Shinobi Therapeutics

About Shinobi Therapeutics

Shinobi Therapeutics is a biotechnology company focused on developing immune-evasive iPS cell therapies to treat cancer and other devastating diseases. Their mission is to engineer therapies that work with the patient's immune system, avoiding rejection and unlocking the full potential of cell therapies through their innovative Katana platform.

Products & Services

NJA-001 (iPS-ɑβ T cell):Targets GPC3+ HLA-A24 solid tumors such as HCC, CRC, and NSCLC. Currently in preclinical stage.

NJA-005 (Pancreatic beta cell):Targets Type 1 Diabetes. Currently in discovery stage.

NJA-201 (iPS-NK cell):Targets autoimmune diseases.

Specialties

Immune-evasive iPS cell therapies CAR-T cell therapies iPSC-derived therapies for cancer and autoimmune diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 59000000 MR: - FA: $59M FAN: 59000000	D: 2024-08-06 FD: 2024-08-06	2 investors
2	RT: Series A T: - FT: Series A	A: 51000000 MR: - FA: 51 million FAN: 51000000	D: 2023-12-12 FD: 2023-12-12	7 investors

Grant Latest

2024-08-06

$59.0M

2 investors (Pro only)

Series A 2023-12-12

$51.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Dan Kemp

CEO

LinkedIn (Pro only)

L

Luis Borges

Chief Scientific Officer

LinkedIn (Pro only)

S

Steven Katz

CMO

LinkedIn (Pro only)

R

Ryosuke Gonotsubo

Co-founder, Head of Japan Operations

Y

Yasumichi Hitoshi

Co-founder, Head of Discovery Japan

Y

Yueting Zheng

VP, Discovery and US site head

View 15 more team members with Pro

Unlock Full Team Directory

Recent News